Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Chimeric Antigen Receptor on T Cells

  • Laurence J. N. Cooper
  • Sourindra N. Maiti
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1092-2




A chimeric antigen receptor (CAR) consists of an extracellular antigen-binding exodomain, typically derived from a single-chain antibody fragment (scFv) of a monoclonal antibody (mAb), a spacer (such as an antibody Fc region), a transmembrane region, and one or more intracellular signaling endodomains, which can be genetically introduced into hematopoietic cells, such as T cells, to redirect specificity for a desired cell-surface antigen.


Background on Manipulating T-Cell Responses to Cancer

Adoptive transfer of tumor-specific T cells in mouse models can function as potent anticancer biological agents leading to the elimination of established malignancies. Continued advances in tumor immunology support the premise and promise for adoptive immunotherapyas a treatment for human malignancies. Yet, infusion of tumor-specific T cells has only been partially successful in clinical oncology trials. Indeed, most of these trials demonstrate the safety...


Human Leukocyte Antigen Adoptive Transfer Chimeric Antigen Receptor Adoptive Immunotherapy Adoptive Cellular Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Cooper L, Topp MS, Serrano LM et al (2003) T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101:1637–1644CrossRefPubMedGoogle Scholar
  2. Eshhar Z, Waks T, Bendavid A et al (2001) Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 248(1–2):67–76CrossRefPubMedGoogle Scholar
  3. Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129CrossRefPubMedPubMedCentralGoogle Scholar
  4. Park JR, Digiusto DL, Slovak M et al (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15(4):825–833PubMedGoogle Scholar
  5. Rossig C, Brenner MK (2003) Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol 110(203):154–159CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Division of Pediatrics, Department of ImmunologyM.D. Anderson Cancer CenterHoustonUSA